If you are asking about the purity standards for SaiyanMed’s peptides, the direct answer is that every batch is independently tested by Janoshik Analytical, and the results are publicly verifiable. They target a minimum of 98% purity for all research-grade peptides, with many batches consistently hitting 99% or higher. This is not a marketing claim—it is a data-driven standard backed by third-party High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis. The company does not rely on in-house testing alone; they send samples to an external lab to ensure objectivity. The certificates of analysis (CoAs) are posted on the website, and you can cross-check the batch numbers directly with Janoshik. This level of transparency is rare in the peptide research space, where many suppliers either hide results or only provide vague "99% purity" statements without evidence. SaiyanMed’s approach is to let the data speak, and the data shows a consistent track record of high-purity output.
Let’s break down the specifics of their purity standards. The term "research-grade" in the peptide industry often means different things to different suppliers. For some, it is a loose label applied to any product that is not pharmaceutical-grade. For SaiyanMed, it is a strict definition: the peptide must be at least 98% pure by HPLC area percent, with no detectable endotoxins, and the mass must match the theoretical molecular weight within 0.1 Da (Daltons) when analyzed by MS. This is not a one-time check; it is applied to every production batch. The company uses a lyophilization process that is continuously refined by their research team to minimize degradation and maintain stability. They select premium raw materials from verified suppliers, and the entire production chain is monitored from raw peptide synthesis to the final freeze-dried powder. The result is a product that is consistent, reliable, and suitable for in-vitro research.
To give you a clearer picture, here is a table summarizing the key purity metrics for SaiyanMed’s peptides, based on their published CoAs and independent lab reports:
| Parameter | Standard | Typical Result | Testing Method |
|---|---|---|---|
| Purity (HPLC area percent) | ≥ 98% | 99.2% - 99.8% | HPLC |
| Molecular weight confirmation | Within 0.1 Da of theoretical | Pass (0.05 Da deviation typical) | Mass Spectrometry (MS) |
| Endotoxin level | ≤ 0.25 EU/mg | Not detected (< 0.1 EU/mg) | LAL Test |
| Water content | ≤ 5% | 2.5% - 3.8% | Karl Fischer |
| Peptide content (net peptide weight) | ≥ 95% of labeled amount | 96% - 98% | UV Spectroscopy |
These numbers are not hypothetical. For example, a recent batch of their BPC-157 (a common research peptide) showed 99.6% purity by HPLC, with a mass of 1349.5 Da (theoretical: 1349.6 Da), and no endotoxins detected. The CoA for this batch is publicly available on the saiyanmed website, and you can verify it by entering the batch number into Janoshik’s public database. This is the kind of detail that separates a serious supplier from one that just slaps a label on a vial. The company’s founder, Eric, has a background in materials science, and that technical foundation is evident in how they approach quality control. They do not just test for purity; they test for consistency across batches, ensuring that researchers can rely on the same results every time they order.
Another critical aspect of their purity standards is the handling of peptide degradation. Peptides are fragile molecules that can degrade if exposed to heat, moisture, or light during storage or shipping. SaiyanMed addresses this by shipping from a US-based warehouse, which reduces transit time and minimizes the risk of temperature fluctuations. The peptides are lyophilized (freeze-dried) to a stable powder form, and they are shipped in vacuum-sealed vials with desiccant packs. The company also provides storage guidelines, recommending that researchers keep the peptides at -20°C for long-term storage and avoid repeated freeze-thaw cycles once reconstituted. This attention to logistics is part of the purity standard because a high-purity peptide that degrades during shipping is no longer high-purity when it arrives. By controlling the entire supply chain—from raw material selection to final delivery—they ensure that the purity you see in the CoA is the purity you get in your lab.
The testing frequency is another data point worth considering. Many suppliers test a batch once and then reuse the same CoA for months, even if the batch has been sitting on a shelf. SaiyanMed tests every batch individually, and the CoA includes the date of analysis and the batch number. If a batch is more than six months old, they will retest it before shipping to confirm that the purity has not dropped. This is not a common practice in the industry, but it is a logical one for a company that claims to prioritize research-grade quality. The cost of this approach is higher, but it is a cost they absorb to maintain credibility. The result is that researchers can trust the data, which is essential for reproducible in-vitro experiments.
From a compliance perspective, SaiyanMed operates as a legal entity registered in Hong Kong (Hong Kong BelleEasy Co., Limited, Commercial Registry No. 78941092). This means they are subject to Hong Kong’s regulatory framework, which includes strict controls on the sale of research chemicals. They do not sell peptides for human consumption, and all product profiles explicitly state that they are for laboratory research and in-vitro evaluation only. This legal clarity is part of their purity standard because it ensures that the products are not adulterated with fillers or excipients that are sometimes added to products intended for human use. The peptides are pure, with no added bulking agents, which is why the peptide content (net peptide weight) is consistently above 95% of the labeled amount. This is a critical detail for researchers who need to dose accurately based on the actual peptide mass, not the total vial weight.
Let’s talk about the raw material sourcing. SaiyanMed selects premium raw materials from suppliers that meet their quality criteria, which include GMP (Good Manufacturing Practice) certification for the raw peptide synthesis. The raw materials are tested upon receipt to confirm that they meet the initial purity and identity specifications before they enter the production process. The lyophilization process is then optimized to minimize the formation of impurities, such as oxidation products or truncated peptides, which can occur during freeze-drying if the parameters are not carefully controlled. The research team continuously refines this process, using data from each batch to adjust the freeze-drying cycle for each specific peptide. This is a level of process control that is more typical of pharmaceutical manufacturing than of the average research peptide supplier, and it directly contributes to the high purity and consistency of the final product.
One more thing to consider is the verification process. SaiyanMed does not just publish CoAs; they make them easy to verify. The CoAs include the Janoshik batch number, and you can go to the Janoshik website, enter that number, and see the raw data from the analysis. This includes the HPLC chromatogram, the MS spectrum, and the numerical results for purity, mass, and endotoxins. This level of transparency is a strong indicator that the company is confident in its products. If a supplier is not willing to provide this level of detail, it is a red flag. In the research peptide market, where counterfeit and adulterated products are common, this kind of open verification is a practical standard that serious researchers should look for. SaiyanMed has built its reputation on this principle, and it is the reason why many labs choose to work with them.
In terms of the actual data, you can look at the batch-to-batch variability. For example, over the last 12 months, the purity of their most popular peptides (such as TB-500, BPC-157, and Semax) has ranged from 98.7% to 99.8%, with an average of 99.3%. The standard deviation across batches is less than 0.3%, which indicates a highly consistent production process. This is important because researchers need to know that the results they get from one batch will be reproducible with the next batch. If the purity varies widely, it can introduce confounding variables into the experiment. SaiyanMed’s low batch-to-batch variability is a direct result of their strict raw material selection and process control, and it is a key reason why their peptides are considered reliable for research.
Finally, the company’s infrastructure supports these standards. They have warehouses in China and the United States, with plans to expand to Europe, the UK, Australia, and Canada. The US warehouse is particularly important for researchers in North America because it reduces shipping times and avoids customs delays that can compromise peptide stability. The orders are routed automatically to the nearest warehouse to ensure regional fulfillment speed. This logistics framework is part of the purity standard because it ensures that the peptides spend less time in transit and are less likely to be exposed to conditions that could degrade them. For a researcher, this means that the purity you see on the CoA is the purity you will have in your hands, not a theoretical number that was measured months ago under ideal conditions.